Skip to main content
TipRanks
Go Ultimate75% OFF

Generic Sweden AB (GENI) AI Stock Analysis

1 Followers
SE:GENI

Generic Sweden AB

(Nasdaq OMX AB:GENI)

Select Model
Rating:83Outperform
Price Target:SEK 42.00â–²(18.64% Upside)
Action:reiterated
Date:08/21/26

The score is driven primarily by strong financial performance (profitability, debt-free balance sheet, and solid free-cash-flow conversion). Valuation is supportive with a moderate P/E and a strong dividend yield, while technicals are positive but not decisively strong enough to push the score higher.

Positive Factors
Strong profitabilityHigh operating and net margins indicate that the company converts revenue into earnings efficiently. Maintaining this profitability provides internal funding for product investment, supports resilience through moderate business fluctuations, and strengthens the potential durability of earnings over the next several quarters.
Negative Factors
Gross margin pressureThe decline in gross margin suggests that cost of revenue has absorbed a larger share of sales than in earlier periods. If sustained, this could limit operating leverage, reduce the benefit of future revenue growth, and make profitability more sensitive to pricing or cost changes.

Generic Sweden AB (GENI) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:GENI-19.29%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 436.98M
Dividend Yield
4.92%
Average Volume (3M)
24.86K
Price to Earnings (P/E)
13.6
Beta (1Y)
0.45
Revenue Growth
6.03%
EPS Growth
-0.15%
Country
Sweden
Employees
21
Sector
Technology
Sector Strength
61
Industry
Software - Application

Generic Sweden AB Business Overview & Revenue Model

Company Description

Operating as a technology firm, Generic Sweden AB delivers messaging functionalities compatible with any application. The company additionally furnishes a comprehensive platform dedicated to digital communication services. Established in 1993, its co...

Generic Sweden AB Financial Statement Overview

Summary

Strong overall fundamentals: solid profitability (TTM operating margin ~20.7%, net margin ~16.5%), very conservative capital structure with zero debt, and healthy cash conversion (TTM operating cash flow slightly above net income; free cash flow ~93% of net income). Key offsets are some gross margin compression versus earlier years and a recent decline in equity/assets that is worth monitoring.

Income Statement

86Very Positive

Balance Sheet

92Very Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue192.18M183.71M176.45M142.59M127.73M114.23M
Gross Profit49.36M38.81M44.72M38.27M35.54M31.93M
EBITDA40.19M39.58M35.52M30.16M26.88M24.25M
Net Income31.79M31.04M27.25M23.31M20.45M18.13M
Balance Sheet
Total Assets97.14M105.14M88.97M77.42M68.04M59.42M
Cash, Cash Equivalents and Short-Term Investments45.78M58.24M40.62M37.20M32.60M31.07M
Total Debt000000
Total Liabilities36.39M38.55M33.75M31.01M29.57M29.11M
Stockholders Equity60.74M66.59M55.22M46.41M38.47M30.31M
Cash Flow
Free Cash Flow31.12M38.98M21.85M19.97M13.82M18.44M
Operating Cash Flow32.79M39.73M24.06M21.84M16.85M19.89M
Investing Cash Flow12.33M-2.44M9.79M-13.87M-3.03M-1.45M
Financing Cash Flow-21.51M-19.67M-18.44M-15.37M-12.29M-9.83M

Generic Sweden AB Technical Analysis

Technical Analysis SentimentNegative
Last Price35.40

Price Trends

50DMA38.21Negative
100DMA38.61Negative
200DMA37.76Negative

Market Momentum

MACD-0.50Positive
RSI35.12Neutral
STOCH2.55Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GENI, the sentiment is Negative. The current price of 35.40 is below the 20-day moving average (MA) of 37.30, below the 50-day MA of 38.21, and below the 200-day MA of 37.76, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 35.12 is Neutral, neither overbought nor oversold. The STOCH value of 2.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GENI.

Generic Sweden AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

SE:GENI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GENISE:GENI83OutperformSEK 436.98M13.62―4.92%6.03%-0.15%
SE:LIMESE:LIME79OutperformSEK 3.43B27.9032.20%1.75%8.57%17.98%
SE:UPSALESE:UPSALE78OutperformSEK 431.06M15.80―8.49%11.34%40.60%
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
SE:ONEFSE:ONEF60NeutralSEK 497.31M-53.18――20.62%85.64%

* Technology Sector Average

Performance Comparison

0%50%100%SE:GENISE:DONESE:LIMESE:UPSALESE:ONEFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:GENI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:GENIGeneric Sweden AB35.40-7.74-17.95%
SE:DONE24Sevenoffice Scandinavia Ab5.48-0.20-3.52%
SE:LIMELime Technologies AB252.50-58.23-18.74%
SE:UPSALEUpsales Technology AB24.90-5.25-17.42%
SE:ONEFOneflow AB17.10-8.90-34.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026